COMMUNIQUÉS West-GlobeNewswire

Rhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés
05/11/2025
IMCIVREE est désormais remboursé pour le cadre de la gestion du poids chez les patients atteints du syndrome de Bardet-Biedl (BBS) en Ontario, en Alberta, en Colombie-Britannique, en Saskatchewan, en Nouvelle-Écosse et [...]
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
05/11/2025
IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHB BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm [...]
HealthEquity Announces Third Quarter Earnings Date
05/11/2025
DRAPER, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest Health Savings Accounts (“HSA") and consumer-directed benefits administrator, [...]
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
05/11/2025
Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has initiated RASolute [...]
PacBio Announces Third Quarter 2025 Financial Results
05/11/2025
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025 Q3 2024 Revenue $38.4 million $40.0 [...]
Pennant Reports Third Quarter 2025 Results
05/11/2025
Conference Call and Webcast scheduled for tomorrow, November 6, 2025 at 10:00 am MT EAGLE, Idaho, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]
Senseonics Holdings, Inc. Reports Third Quarter Financial Results
05/11/2025
Generated Q3 revenue of $8.1 million, representing year-over-year growth of 90% Achieved a 160% increase in U.S. new patient starts over prior year Planning for the transition of CGM commercial responsibility from [...]
Adaptive Biotechnologies Reports Third Quarter 2025 Financial Results
05/11/2025
SEATTLE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive [...]
Rapport Therapeutics to Participate in Upcoming Investor Conferences
05/11/2025
BOSTON and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small [...]
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
05/11/2025
BELTSVILLE, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to [...]
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
05/11/2025
RADNOR, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities [...]
OraSure Announces Third Quarter 2025 Financial Results
05/11/2025
BETHLEHEM, Pa., Nov. 05, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for [...]
RxSight, Inc. Reports Third Quarter 2025 Financial Results
05/11/2025
ALISO VIEJO, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update
05/11/2025
3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase 3Q 2025 Adjusted Net Income (2) of [...]
Cytek Biosciences Reports Third Quarter 2025 Financial Results
05/11/2025
FREMONT, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Cytek ® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third [...]
CVRx Reports Third Quarter 2025 Financial and Operating Results
05/11/2025
MINNEAPOLIS, Nov. 05, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions [...]
Generation Bio Announces Third Quarter 2025 Financial Results
05/11/2025
CAMBRIDGE, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company, today reported third quarter financial results. Third Quarter 2025 Financial Results Cash Position: Cash, [...]
Zevra Reports Third Quarter 2025 Financial Results and Corporate Update
05/11/2025
2025 EPS of $(0.01) Q3 2025 net revenue of $26.1 million , driven by MIPLYFFA ® net revenue of $22.4 million Company to host conference call and webcast TODAY, November 5, 2025 , at 4:30 p.m. ET CELEBRATION, Fla., Nov. [...]
Neurona Therapeutics Announces Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to NRTX-1001 in the Treatment of Drug-Resistant Focal Epilepsy
05/11/2025
EMA’s PRIME designation bolsters Neurona’s global development strategy and underscores the company’s commitment to bringing NRTX-1001 interneuron cell therapy to patients worldwide. SAN FRANCISCO, Nov. 05, 2025 (GLOBE [...]

Pages